- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07946757
Phase Ib Clinical Trial of ACT201 Injection in Participants With Treatment-Naïve Chronic Hepatitis B
A Multicenter, Randomized, Open-Label Phase Ib Clinical Trial to Evaluate the Safety and Efficacy of ACT201 Injection in Participants With Treatment-Naïve Chronic Hepatitis B(CHB)
This is a multicenter, randomized, open-label, parallel-controlled phase Ib clinical trial, which aims to evaluate the safety and preliminary efficacy of ACT201 injection combined with standard-of-care therapy (PegIFNα, NAs) in treatment-naive participants with chronic hepatitis B. A total of 60 treatment-naive participants with chronic hepatitis B are planned to be enrolled and randomized Treatment Group 1, Treatment Group 2, Treatment Group 3 or Treatment Group 4 for treatment.
Studieoversigt
Status
Betingelser
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 1
Kontakter og lokationer
Studiekontakt
- Navn: Minghui Li, Ph.D
- Telefonnummer: 010-84322284
- E-mail: Wuhm2000@sina.com
Studiesteder
-
-
-
Beijing, Kina
- Beijing Ditan Hospital, Capital Medical University
-
Kontakt:
- Minghui Li
-
Xi'an, Kina
- The Second Affiliated Hospital of Xi'an Jiaotong University
-
Kontakt:
- Shuangsuo Dang
-
Xiamen, Kina
- The First Affiliated Hospital of Xiamen University
-
Kontakt:
- Xiulan Xue
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Voluntarily participate in this trial and sign the informed consent form;
- Aged 18 to 65 years (inclusive), male or female;
- Body mass index (BMI) between 18 and 32 kg/m² (inclusive);
- HBsAg-positive or HBV DNA-positive for at least 6 months, or previous liver biopsy showing chronic HBV infection, or HBsAg-positive and anti-HBc IgM-negative at screening;
- No prior treatment with nucleos(t)ide analogues or interferons for chronic hepatitis B within 6 months before screening;
- HBsAg, HBeAg, HBV DNA and liver function indicators meet the protocol requirements;
- Willing to use effective contraception and have no plan for pregnancy, sperm donation or oocyte donation.
Exclusion Criteria:
- Subjects with recent major trauma or major surgery, or those scheduled to undergo surgery;
- Presence of clinically significant uncontrolled abnormalities or other severe diseases other than chronic HBV infection;
- History of other liver diseases;
- History of liver cirrhosis;
- Imaging suggestive of a suspected malignant hepatic lesion;
- Past or current evidence of hepatic decompensation;
- History of extrahepatic diseases potentially associated with HBV immune status;
- Other diseases associated with vasculitis;
- Infections (other than HBV) requiring systemic antiviral or antibacterial therapy at screening;
- History of malignancy;
- Prior solid organ or bone marrow transplantation;
- Presence or history of severe psychiatric disorders;
- Severe retinopathy or other serious ophthalmic diseases;
- Prior or current use of prohibited medications;
- Concomitant hematological diseases;
- Abnormal laboratory findings;
- Abnormal QTcF interval;
- History of allergy;
- Lactating female subjects or those with a positive serum pregnancy test at screening;
- Participation in another clinical trial, or failure to complete the washout period specified in the protocol prior to this trial;
- Any other condition that, in the opinion of the investigator, renders the subject unsuitable for participation in this trial.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Gruppe 2
|
Subcutaneous injection per assigned treatment group; Treatment duration and dosing sequence shall be in accordance with the study protocol Subcutaneous injection per assigned treatment group; Treatment duration and dosing sequence shall be in accordance with the study protocol Subcutaneous injection per assigned treatment group; Treatment duration shall follow the study protocol Once daily, orally, until the end of the trial |
|
Eksperimentel: Gruppe 1
|
Subcutaneous injection per assigned treatment group; Treatment duration and dosing sequence shall be in accordance with the study protocol Subcutaneous injection per assigned treatment group; Treatment duration and dosing sequence shall be in accordance with the study protocol Subcutaneous injection per assigned treatment group; Treatment duration shall follow the study protocol Once daily, orally, until the end of the trial |
|
Eksperimentel: Gruppe 3
|
Subcutaneous injection per assigned treatment group; Treatment duration and dosing sequence shall be in accordance with the study protocol Subcutaneous injection per assigned treatment group; Treatment duration and dosing sequence shall be in accordance with the study protocol Subcutaneous injection per assigned treatment group; Treatment duration shall follow the study protocol Once daily, orally, until the end of the trial |
|
Eksperimentel: Gruppe 4
|
Subcutaneous injection per assigned treatment group; Treatment duration and dosing sequence shall be in accordance with the study protocol Subcutaneous injection per assigned treatment group; Treatment duration shall follow the study protocol Once daily, orally, until the end of the trial |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Safety: number of participants with adverse event (AE), serious adverse events (SAE) and clinically significant examination results. Assessments include vital signs, physical examinations, laboratory tests, and 12-lead electrocardiograms (ECGs)
Tidsramme: throughout the full study period,an average of 38 weeks
|
throughout the full study period,an average of 38 weeks
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
HBsAg, HBsAb and HBV DNA levels and changes from baseline
Tidsramme: throughout the full study period,an average of 38 weeks
|
throughout the full study period,an average of 38 weeks
|
|
HBsAg seroclearance rate
Tidsramme: throughout the full study period,an average of 38 weeks
|
throughout the full study period,an average of 38 weeks
|
|
HBsAg seroconversion rate
Tidsramme: throughout the full study period,an average of 38 weeks
|
throughout the full study period,an average of 38 weeks
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Minghui Li, Ph.D, Beijing Ditan Hospital
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Andre undersøgelses-id-numre
- ACT201-4-1-002
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .